2020 in cancer

FDA · US: 168 records / 70 drugsHealth Canada · CA: 50 records / 28 drugsEMA · EU: 23 records / 20 drugs

• Dec 18, 2020Relugolix FDA · US original application approved Malignant Prostate NeoplasmORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer. ORGOVYX is a gonadotropin-releasing hormone (GnRH) receptor antagonist…openfda
• Dec 16, 2020Margetuximab FDA · US original application approved HER2-Positive Breast CarcinomaMARGENZA is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two…openfda
• Nov 9, 2020Erlotinib FDA · US original application approved Malignant Pancreatic NeoplasmFirst-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.openfda
• Nov 9, 2020Erlotinib FDA · US original application approved Lung Non-Small Cell CarcinomaThe treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or…openfda
• Nov 9, 2020Erlotinib FDA · US original application approved Lung Non-Small Cell CarcinomaLimitations of Use: Safety and efficacy of erlotinib tablets have not been established in patients with NSCLC whose tumors have other EGFR mutations.openfda
• Sep 4, 2020Pralsetinib FDA · US original application accelerated approved Malignant Thyroid Gland NeoplasmAdult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are…openfda
• Sep 4, 2020Pralsetinib FDA · US original application approved Lung Non-Small Cell CarcinomaAdult patients with metastatic rearranged during transfection (RET ) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).openfda
• Sep 1, 2020Azacitidine FDA · US original application approved Acute Myeloid LeukemiaONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with…openfda
• Aug 21, 2020Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell Carcinomaas a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.openfda
• Aug 21, 2020Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell Carcinomain combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.openfda
• Aug 21, 2020Pemetrexed FDA · US original application approved Lung Non-Small Cell CarcinomaLimitations of Use: Pemetrexed Injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer.openfda
• Aug 21, 2020Pemetrexed FDA · US original application approved Pleural Malignant Mesotheliomainitial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not…openfda
• Aug 21, 2020Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell Carcinomaas a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four…openfda
• Aug 4, 2020Enzalutamide FDA · US original application approved Castration-Resistant Prostate Carcinomacastration-resistant prostate cancer (CRPC)openfda
• Aug 4, 2020Enzalutamide FDA · US original application approved Nonmetastatic Castration-Sensitive Prostate Carcinomanon‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR) XTANDI is an androgen…openfda
• Aug 4, 2020Enzalutamide FDA · US original application approved Malignant Prostate Neoplasmmetastatic castration-sensitive prostate cancer (mCSPC)openfda
• Aug 4, 2020Enzalutamide FDA · US original application approved Malignant Prostate Neoplasmnon‑metastatic castration‑sensitive prostate cancer with biochemical recurrence at high risk for metastasis. ( 1 )openfda
• Aug 4, 2020Enzalutamide FDA · US original application approved Malignant Prostate Neoplasmmetastatic castration-sensitive prostate cancer. ( 1 )openfda
• Aug 4, 2020Enzalutamide FDA · US original application approved Castration-Resistant Prostate Carcinomacastration-resistant prostate cancer. ( 1 )openfda
• Jul 31, 2020Tafasitamab FDA · US original application approved Marginal Zone LymphomaLimitations of Use : MONJUVI is not indicated and is not recommended for the treatment of patients with relapsed or refractory marginal zone lymphoma outside…openfda
• Jul 31, 2020Tafasitamab FDA · US original application approved Follicular Lymphomain combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).openfda
• Jul 31, 2020Tafasitamab FDA · US original application accelerated approved Diffuse Large B-Cell Lymphomain combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified,…openfda
• Jun 15, 2020Lurbinectedin FDA · US original application approved Lung Small Cell Carcinomain combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, for the maintenance treatment of adult patients with extensive-stage small cell lung…openfda
• Jun 15, 2020Lurbinectedin FDA · US original application approved Lung Small Cell CarcinomaFor the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.openfda
• May 8, 2020Selpercatinib FDA · US original application approved Lung Non-Small Cell CarcinomaAdult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by…openfda
• May 8, 2020Selpercatinib FDA · US original application approved Thyroid Gland Medullary CarcinomaAdult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an…openfda
• May 8, 2020Selpercatinib FDA · US original application approved Malignant Thyroid Gland NeoplasmAdult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test,…openfda
• May 6, 2020Capmatinib FDA · US original application approved Lung Non-Small Cell CarcinomaTABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to…openfda
• May 1, 2020Leuprolide FDA · US original application approved Conventional OsteosarcomaFENSOLVI ® is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP). FENSOLVI is a gonadotropin…openfda
• Apr 22, 2020Sacituzumab Govitecan FDA · US original application approved Triple-Negative Breast CarcinomaLocally Advanced or Metastatic Triple-Negative Breast Cancer First Line As a single agent for the first-line treatment of adult patients with unresectable…openfda
• Apr 22, 2020Sacituzumab Govitecan FDA · US original application approved Triple-Negative Breast CarcinomaIn combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of adult patients with unresectable locally…openfda
• Apr 22, 2020Sacituzumab Govitecan FDA · US original application approved Malignant Breast NeoplasmLocally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer For the treatment of adult patients with unresectable locally advanced or metastatic…openfda
• Apr 17, 2020Tucatinib FDA · US original application approved Malignant Colorectal Neoplasmin combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has…openfda
• Apr 17, 2020Tucatinib FDA · US original application approved HER2-Positive Breast Carcinomain combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer,…openfda
• Apr 17, 2020Pemigatinib FDA · US original application accelerated approved CholangiocarcinomaCholangiocarcinoma PEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma…openfda
• Mar 2, 2020Isatuximab FDA · US original application approved Multiple MyelomaSARCLISA is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least…openfda
• Feb 8, 2020Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell Carcinomaas a single agent for the treatment of patients with recurrent, metastatic non-squamous NSCLC after prior chemotherapy.openfda
• Feb 8, 2020Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell Carcinomain combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK…openfda
• Feb 8, 2020Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell Carcinomaas a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous NSCLC whose disease has not progressed after four…openfda
• Feb 8, 2020Pemetrexed FDA · US original application approved Lung Non-Small Cell CarcinomaLimitations of Use : PEMFEXY is not indicated for the treatment of patients with squamous cell non-small cell lung cancer.openfda
• Feb 8, 2020Pemetrexed FDA · US original application approved Pleural Malignant Mesotheliomain combination with cisplatin for the initial treatment, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not…openfda
• Feb 8, 2020Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell Carcinomain combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC).openfda
• Jan 23, 2020Tazemetostat FDA · US original application approved Follicular LymphomaAdult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have…openfda
• Jan 23, 2020Tazemetostat FDA · US original application approved Epithelioid SarcomaAdults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.openfda
• Jan 23, 2020Tazemetostat FDA · US original application approved Follicular LymphomaAdult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.openfda
• Dec 14, 2020Tirbanibulin FDA · US original application approved cancer not stated in this recordKLISYRI is indicated for the topical field treatment of actinic keratosis on the face or scalp. KLISYRI is a microtubule inhibitor indicated for the topical…openfda
• Nov 20, 2020Lonafarnib FDA · US original application approved cancer not stated in this recordZOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m 2 and above: To reduce the risk of mortality in…openfda
• Nov 9, 2020Erlotinib FDA · US original application approved cancer not stated in this recordErlotinib tablets are not recommended for use in combination with platinum-based chemotherapy.openfda
• Sep 25, 2020Tofacitinib FDA · US original application approved cancer not stated in this recordModerately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers. • Active psoriatic…openfda
• Aug 21, 2020Pemetrexed FDA · US original application approved cancer not stated in this recordin combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer…openfda
• Jul 30, 2020Cyclophosphamide FDA · US original application approved cancer not stated in this recordCyclophosphamide is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Diseases: malignant lymphomas: Hodgkin's…openfda
• Jun 15, 2020Lurbinectedin FDA · US original application accelerated approved cancer not stated in this recordThis indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be…openfda
• May 15, 2020Ripretinib FDA · US original application approved cancer not stated in this recordQINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more…openfda
• May 8, 2020Selpercatinib FDA · US original application approved tumor-agnosticAdult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved…openfda
• May 5, 2020Celecoxib FDA · US original application approved cancer not stated in this recordELYXYB is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ELYXYB is not indicated for the preventive treatment…openfda
• Apr 22, 2020Sacituzumab Govitecan FDA · US original application approved cancer not stated in this recordSecond Line or Later For the treatment of adult patients with unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at…openfda
• Apr 17, 2020Tucatinib FDA · US original application accelerated approved cancer not stated in this recordThis indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.2) ]. Continued…openfda
• Apr 17, 2020Pemigatinib FDA · US original application approved cancer not stated in this recordMyeloid/Lymphoid Neoplasms with FGFR1 Rearrangement PEMAZYRE is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms…openfda
• Apr 15, 2020Mitomycin FDA · US original application approved cancer not stated in this recordJELMYTO ® is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). JELMYTO is an alkylating drug indicated for…openfda
• Apr 10, 2020Selumetinib FDA · US original application approved cancer not stated in this recordKOSELUGO is indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic,…openfda

RegulatoryAll 2020 records with filters →

Studies

6,928

Interventional

5,238

Phase III

462

Industry-led

1,482

With posted results

844

Countries with sites

103

Published source: clinicaltrials · first_posted_date as posted